Fanconi syndrome medical therapy

Fanconi syndrome Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Fanconi syndrome from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study Of Choice
History and Symptoms
Physical Examination
Laboratory Findings
X Ray
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Fanconi syndrome medical therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Fanconi syndrome medical therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Fanconi syndrome medical therapy
CDC on Fanconi syndrome medical therapy
Fanconi syndrome medical therapy in the news
Blogs on Fanconi syndrome medical therapy
Directions to Hospitals Treating Fanconi syndrome
Risk calculators and risk factors for Fanconi syndrome medical therapy

TyrosinemiaEditor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

Definitive treatment of Fanconi syndrome in most of the cases is the treatment of the underlying cause( which sometimes is not practical) and resolving the exposure to the contributor compounds(In exogenous causes/Tyrosinemia/ Galactosemia/ Hereditary fructose intolerance).

Temporary treatment involves replacement therapy which is the current mainstay of therapy. Replacement therapy regimen is depended on the severity of disease and the extent of urinary loss of each ingredient and therefore varies substantially among individuals.

Some of the most important concepts of cause-specific medical therapies is described below.

Medical Therapy

Fanconi syndrome due to Cystinosis

• 1.1.1 Adult and Pediatric

• Cystine-lowering Agents
  • Preferred regimen (1): Cysteamine 60-90 mg/kg/day q.i.d. every 6 h (specific instructions: <1 years: Safety and efficacy not established)
• Chelating agents
  • Preferred regimen (2): Penicillamine 30 mg/kg/day PO divided BID/QID

Fanconi syndrome due to Wilson disease

• 2.1.1 Adult and pediatrics
• Removal of the copper:
  • Preferred regimen (1): D-penicillamine 20 mg/kg PO q12h
  • Alterantive regimen (1):  Trientine hydrochloride 500 to 750 mg PO q12h/q6h
• Preventing reaccumulation:
  • Preferred regimen (1): Zinc acetate PO 50 mg q8h

Fanconi syndrome due to Tyrosinemia

• 2.1.1 Adult and pediatrics
•  Preferred regimen (1): NTBC 1 mg/kg/day